Advanced Hepatocellular Carcinoma
Feasibility of Sorafenib Combined with Local Radiotherapy in Advanced Hepatocellular Carcinoma
... for advanced hepatocellular car- ...of advanced hepatocellular carcinoma and encourage the initiation of a controlled clinical ...
8
Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma
... for advanced hepatocellular carcinoma (HCC) has changed ...with advanced HCC compared with ...with advanced HCC who are resistant, show progression or do not tolerate ...
13
Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma
... of advanced hepatocellular carcinoma ...of advanced HCC. Keywords: hepatocellular carcinoma, receptor tyrosine kinase inhibitor, sorafenib, regorafenib, lenvatinib, tivantinib, ...
6
Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study
... treat advanced hepatocellular carcinoma (HCC), though it is unclear how much benefit advanced HCC patients with progressive disease (PD) derive from sorafenib ...for advanced HCC ...
10
Efficacy of 5 Fluorouracil and High Concentration Cisplatin Suspended in Lipiodol by Short Term Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis
... Since advanced hepatocellular carcinoma (HCC) is potentially fatal, and patients’ quality of life (QOL) often deteriorates during their treatment, improving the prognosis and QOL of patients given ...
11
Emerging therapies in advanced hepatocellular carcinoma
... for advanced HCC for almost a decade until recent pro- gress [8, ...for advanced HCC has made nearly no progress since the approval of sorafenib until ...
9
Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives
... of sorafenib as an adjuvant therapy for HCC after curative therapy has been explored in the placebo-controlled, random- ized Phase III STORM (Sorafenib as adjuvant Treatment in the Prevention Of Recurrence of ...
15
<p>Japanese patient preferences regarding intermediate to advanced hepatocellular carcinoma treatments</p>
... in advanced cases Regular visits to the hospital (once every 1-2 weeks) are needed to refill the chemotherapy Surgery performed under sedation that requires several hours with hospitalization A small container and ...
11
Concomitant Chemoradiation Using Gemcitabine in Locally Advanced Hepatocellular Carcinoma
... [28] Lombardi, G., Pastorelli, D., Zustovich, F., Farina, L., Furini, A., Cappetta, V., et al . (2010) Factors Predicting Time-to-Progression (TTP) and Overall Survival (OS) in Patients with Unresectable ...
12
Fatal adverse events with molecular targeted agents in the treatment of advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials
... toxicities of brivanib in the treatment of advanced HCC, which suggested that brivanib had more toxicities than the placebo. Then, we performed subgroup analysis accord- ing to the specific targeted drugs, and ...
7
Combination treatment including targeted therapy for advanced hepatocellular carcinoma
... Cell signal pathway reactivation, which is induced by mutation of downstream components, is the primary mechanism of resistance to MTAs [45]. In HCC, both the RAS/RAF/MEK/ERK pathway and the PI3K/Akt/mTOR pathway can be ...
16
Efficacy and safety of TACE in combination with sorafenib for the treatment of TACE-refractory advanced hepatocellular carcinoma in Chinese patients: a retrospective study
... Methods: This retrospective study included 61 patients with TACE-refractory advanced HCC. Patients were divided into TACE + SOR (n = 30) and TACE (n = 31) treatment groups. Patient demographic and clinical ...
8
Original Article The efficacy and safety of LDF, a Chinese herbal formula, compared with sorafenib for the treatment of advanced hepatocellular carcinoma in Chinese patients: a retrospective cohort study
... an advanced HCC patient until the occurrence of death for any cause or until the last follow-up time on September 10, 2019; (2) The secondary outcomes consisted of TTP and ...for advanced HCC until the ...
8
Epidemiologic and Clinicopathologic Features of Advanced Hepatocellular Carcinoma
... Background: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide as well as in Egypt where it constitutes a signif- icant public health ...of advanced HCC in clinical ...
11
<p>A real-life experience of sorafenib treatment for patients with advanced hepatocellular carcinoma: a retrospective analysis at Cathay General Hospital, 2007–2015</p>
... Patients previously receiving local therapy (eg, surgery, radiation, hepatic artery embolization, TACE, RFA, percuta- neous ethanol injection, or cryoablation) were eligible under following conditions: local therapy is ...
8
Efficacy and Toxicity of Metronomic Capecitabine in Advanced Hepatocellular Carcinoma
... daily in a 21 days cycle without interruption till disease progression or toxicity. Results: The study cohort consisted of 22 patients with a median age of 63 years. The median number of cycles received was 3 cycles ...
7
Better Management of Adverse Events Favors Sorafenib Treatment of HCC Patients and Impact on Survival
... of advanced hepatocellular carcinoma (HCC) and is the only systemic treatment associated with a survival benefit in advanced ...with advanced HCC treated with ...Conclusions: ...
10
Objective Response by mRECIST is an Independent Prognostic Factor for overall Survival in Hepatocellular Carcinoma in SILIUS Trial
... 24. Kudo, M.; Ueshima, K.; Yokosuka, O.; Ogasawara, S.; Obi, S.; Izumi, N.; Aikata, H.; Nagano, H.; Hatano, E.; Sasaki, Y., et al. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy ...
27
Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib
... Abstract: Sorafenib is an oral kinase inhibitor that enhances survival in patients affected by advanced hepatocellular carcinoma (HCC). According to the results of two registrative trials, this drug ...
11
Time to Progression of AFP (TPA) as a Predictor of Survival in Hepatocellular Carcinoma Treated with Sorafenib (SOR)
... Worldwide, HCC is the sixth cause of cancer mortality in women and the second cause in men [1]. The standard therapy for advanced hepatocellular carcinoma (HCC) is Sorafenib (SOR). Two randomized ...
13